Ablynx NV (XBRU:ABLXS) Days Payable : 0.00 (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV Days Payable?

Ablynx NV's average Accounts Payable for the six months ended in Dec. 2017 was €4.76 Mil. Ablynx NV's Cost of Goods Sold for the six months ended in Dec. 2017 was €0.00 Mil.

The historical rank and industry rank for Ablynx NV's Days Payable or its related term are showing as below:

During the past 12 years, Ablynx NV's highest Days Payable was 80.92. The lowest was 0.00. And the median was 23.58.

XBRU:ABLXS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 134.39
* Ranked among companies with meaningful Days Payable only.

Ablynx NV's Days Payable stayed the same from Dec. 2016 (0.00) to Dec. 2017 (0.00).

Ablynx NV Days Payable Historical Data

The historical data trend for Ablynx NV's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Days Payable Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Days Payable

Get a 7-Day Free Trial

32.52

25.79

15.92

17.73

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
Days Payable	Get a 7-Day Free Trial															18.09	-	-	-	-

Competitive Comparison of Ablynx NV's Days Payable

For the Biotechnology subindustry, Ablynx NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ablynx NV's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's Days Payable distribution charts can be found below:

* The bar in red indicates where Ablynx NV's Days Payable falls into.

Ablynx NV Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Ablynx NV's Days Payable for the fiscal year that ended in Dec. 2017 is calculated as

	Days Payable (A: Dec. 2017 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2016 )	+	Accounts Payable (A: Dec. 2017 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2017 )	*	Days in Period
=	( (5.519	+	4.761)	/	2 )	/	0	*	365
=	5.14					/	0	*	365
=	N/A

Ablynx NV's Days Payable for the quarter that ended in Dec. 2017 is calculated as:

	Days Payable (Q: Dec. 2017 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2017 )	+	Accounts Payable (Q: Dec. 2017 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2017 )	*	Days in Period
=	( (0	+	4.761)	/	1 )	/	0	*	365 / 2
=	4.761					/	0	*	365 / 2
=	N/A

Ablynx NV Days Payable Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV Headlines

No Headlines